Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IAPP | P10997 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23250713 | 0.85 | GABRA1 (0.61) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL199730 | 0.83 | GABRA1 (1.00) | GABRA1GABRB2PTPN5IAPP | |
| SCHEMBL2050917 | 0.83 | GABRA1 (0.46) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL27729786 | 0.82 | ALB (0.47) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL26109749 | 0.81 | ALB (0.45) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL15107549 | 0.81 | GABRA1 (0.45) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL28005176 | 0.81 | IAPP (0.47) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL28357376 | 0.79 | ANO1 (0.47) | GABRA1GABRB2ALBERN1ANO1 | |
| SCHEMBL27809647 | 0.79 | ALOX5 (0.53) | GABRA1GABRB2NR1H2NR1H3IAPP | |
| SCHEMBL2642807 | 0.79 | ALB (0.43) | GABRA1GABRB2ALBERN1ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-04-07 | — | — | US | disclosed |
| US-11242350-B2 | Spirocyclic ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210053976-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-02-25 | — | — | US | disclosed |
| EP-3765020-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | Escalier Biosciences B.V. (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| CN-112118841-A | Spirocyclic ROR-gamma modulators | 爱思凯利尔生物科学私人有限责任公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
| WO-2019177997-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0816349-A1 | NOVEL CLATHRATE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND COATING COMPOSITION CONTAINING SAID NOVEL CLATHRATE COMPOUND | ROHM AND HAAS COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | GABRA1 322/4885GABRB2 182/4885ALB 3218/4885 |
| US-11242350-B2 | Spirocyclic ROR-gamma modulators | RORA, RORC, RORB | GABRA1 188/4885GABRB2 175/4885ALB 2638/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | GABRA1 1141/4885GABRB2 2290/4885ALB 3717/4885 |
| US-20220162209-A1 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | ADSL, SLC35B2, ADORA1 | GABRA1 1989/4885GABRB2 2620/4885ALB 1823/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | GABRA1 933/4885GABRB2 1739/4885ALB 1873/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | GABRA1 252/4885GABRB2 179/4885ALB 4350/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | GABRA1 4619/4885GABRB2 4676/4885ALB 2703/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | GABRA1 4471/4885GABRB2 4726/4885ALB 2646/4885 |
| US-20220106323-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | GABRA1 188/4885GABRB2 175/4885ALB 2638/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | GABRA1 4471/4885GABRB2 4726/4885ALB 2646/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | GABRA1 322/4885GABRB2 182/4885ALB 3218/4885 |
| US-20210053976-A1 | SPIROCYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | GABRA1 146/4885GABRB2 174/4885ALB 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.